DOCSLIB.ORG

Mouse Zmiz1 Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Zmiz1 Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Zmiz1 Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Zmiz1 conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Zmiz1 gene (NCBI Reference Sequence: NM_183208 ; Ensembl: ENSMUSG00000007817 ) is located on Mouse chromosome 14. 24 exons are identified, with the ATG start codon in exon 4 and the TGA stop codon in exon 24 (Transcript: ENSMUST00000162645). Exon 7 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Zmiz1 gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP23-259E22 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Mice homozygous for a null mutation display embryonic lethality during organogenesis with failure of yolk sac vascular remodeling and abnormal embryonic vascular development. Exon 7 starts from about 8.83% of the coding region. The knockout of Exon 7 will result in frameshift of the gene. The size of intron 6 for 5'-loxP site insertion: 54199 bp, and the size of intron 7 for 3'-loxP site insertion: 7540 bp. The size of effective cKO region: ~645 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele gRNA region 5' gRNA region 3' 1 7 24 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Zmiz1 Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(7145bp) | A(23.12% 1652) | C(25.92% 1852) | T(25.68% 1835) | G(25.28% 1806) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. No significant high GC-content region is found. So this region is suitable for PCR screening or sequencing analysis. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr14 + 25632624 25635623 3000 browser details YourSeq 166 2143 2377 3000 92.0% chr5 + 28549975 28550214 240 browser details YourSeq 166 2133 2367 3000 93.8% chr4 + 119152193 119152595 403 browser details YourSeq 163 2138 2376 3000 90.3% chr4 + 81103528 81103775 248 browser details YourSeq 161 2175 2376 3000 92.4% chrX - 129423121 129423352 232 browser details YourSeq 158 2143 2378 3000 90.4% chr3 + 23868053 23868315 263 browser details YourSeq 156 2176 2377 3000 91.7% chr6 + 70867644 70867876 233 browser details YourSeq 154 2175 2404 3000 89.4% chr10 + 55506593 55506843 251 browser details YourSeq 153 2173 2576 3000 81.8% chrX - 157473356 157473609 254 browser details YourSeq 153 2175 2378 3000 90.6% chr15 - 54059135 54059367 233 browser details YourSeq 152 2168 2379 3000 90.2% chr6 - 33860538 33860776 239 browser details YourSeq 152 2045 2378 3000 82.0% chr15 - 25311840 25312100 261 browser details YourSeq 150 2189 2375 3000 93.2% chr7 + 142877611 142877827 217 browser details YourSeq 149 2146 2367 3000 91.7% chr7 + 52011144 52011387 244 browser details YourSeq 148 2145 2377 3000 93.7% chr17 - 70684497 70684737 241 browser details YourSeq 147 2169 2378 3000 91.3% chr16 - 53040232 53040677 446 browser details YourSeq 147 2176 2377 3000 90.3% chr11 - 7852332 7852580 249 browser details YourSeq 146 2173 2378 3000 89.8% chr12 - 37029749 37029986 238 browser details YourSeq 145 2123 2378 3000 88.8% chr1 + 51670691 51670956 266 browser details YourSeq 144 2139 2346 3000 87.3% chr5 - 109813731 109813925 195 Note: The 3000 bp section upstream of Exon 7 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr14 + 25636269 25639268 3000 browser details YourSeq 82 976 1338 3000 94.8% chr11 - 114810791 114811226 436 browser details YourSeq 47 970 1032 3000 94.4% chr17 + 47207675 47208136 462 browser details YourSeq 44 976 1035 3000 95.9% chr6 - 125973587 125974127 541 browser details YourSeq 44 957 1015 3000 80.5% chr12 - 113128791 113128837 47 browser details YourSeq 41 970 1015 3000 95.7% chr9 - 64448756 64448802 47 browser details YourSeq 41 968 1019 3000 95.7% chr9 + 57414227 57414286 60 browser details YourSeq 41 970 1020 3000 97.7% chr2 + 90538058 90538109 52 browser details YourSeq 41 972 1021 3000 95.7% chr1 + 7029595 7029645 51 browser details YourSeq 39 966 1015 3000 90.0% chr1 - 36933346 36933396 51 browser details YourSeq 39 1016 1077 3000 95.5% chr19 + 45325901 45326063 163 browser details YourSeq 39 973 1021 3000 97.6% chr14 + 63108768 63108817 50 browser details YourSeq 39 970 1019 3000 97.6% chr11 + 76476877 76476928 52 browser details YourSeq 39 959 1021 3000 77.3% chr11 + 45860304 45860357 54 browser details YourSeq 38 971 1018 3000 97.5% chr9 - 60177999 60178047 49 browser details YourSeq 38 981 1021 3000 97.6% chr7 - 117949462 117949503 42 browser details YourSeq 38 981 1021 3000 97.6% chr7 - 76237005 76237046 42 browser details YourSeq 38 976 1016 3000 97.6% chr15 + 102286316 102286357 42 browser details YourSeq 37 970 1019 3000 93.1% chr9 - 109904853 109904903 51 browser details YourSeq 37 951 1014 3000 86.3% chr6 - 40668851 40668916 66 Note: The 3000 bp section downstream of Exon 7 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Zmiz1 zinc finger, MIZ-type containing 1 [ Mus musculus (house mouse) ] Gene ID: 328365, updated on 12-Aug-2019 Gene summary Official Symbol Zmiz1 provided by MGI Official Full Name zinc finger, MIZ-type containing 1 provided by MGI Primary source MGI:MGI:3040693 See related Ensembl:ENSMUSG00000007817 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as Rai17; Zimp10; Gm10397; BC065120; E330020C23; I920194n01 Expression Ubiquitous expression in adrenal adult (RPKM 35.4), limb E14.5 (RPKM 30.1) and 27 other tissues See more Orthologs human all Genomic context Location: 14; 14 A3 See Zmiz1 in Genome Data Viewer Exon count: 27 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 14 NC_000080.6 (25457875..25666743) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 14 NC_000080.5 (26278778..26484205) Chromosome 14 - NC_000080.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 8 transcripts Gene: Zmiz1 ENSMUSG00000007817 Description zinc finger, MIZ-type containing 1 [Source:MGI Symbol;Acc:MGI:3040693] Gene Synonyms Rai17, Zimp10 Location Chromosome 14: 25,459,185-25,666,743 forward strand. GRCm38:CM001007.2 About this gene This gene has 8 transcripts (splice variants), 197 orthologues, 5 paralogues, is a member of 1 Ensembl protein family and is associated with 16 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Zmiz1-208 ENSMUST00000162645.7 7482 1072aa ENSMUSP00000124863.1 Protein coding CCDS26873 Q6P1E1 TSL:1 GENCODE basic APPRIS P3 Zmiz1-201 ENSMUST00000007961.14 5397 1066aa ENSMUSP00000007961.8 Protein coding CCDS79280 Q6P1E1 TSL:1 GENCODE basic APPRIS ALT1 Zmiz1-202 ENSMUST00000159766.7 4314 No protein - Retained intron - - TSL:2 Zmiz1-206 ENSMUST00000161766.7 2225 No protein - Retained intron - - TSL:1 Zmiz1-207 ENSMUST00000162546.1 460 No protein - Retained intron - - TSL:2 Zmiz1-204 ENSMUST00000160229.1 930 No protein - lncRNA - - TSL:3 Zmiz1-203 ENSMUST00000160190.1 359 No protein - lncRNA - - TSL:3 Zmiz1-205 ENSMUST00000160680.2 342 No protein - lncRNA - - TSL:5 Page 6 of 8 https://www.alphaknockout.com 227.56 kb Forward strand 25.45Mb 25.50Mb 25.55Mb 25.60Mb 25.65Mb Genes (Comprehensive set... Gm17747-201 >lncRNA Gm47921-201 >lncRNA Mir3075-201 >miRNA Zmiz1-203 >lncRNA Zmiz1-207 >retained intron Zmiz1-206 >retained intron Zmiz1-204 >lncRNA Zmiz1-208 >protein coding Zmiz1-201 >protein coding Zmiz1-202 >retained intron Gm47920-201 >lncRNA Zmiz1-205 >lncRNA Contigs AC157650.2 > < AC154455.2 Genes < Zmiz1os1-202lncRNA (Comprehensive set... < Zmiz1os1-201lncRNA Regulatory Build 25.45Mb 25.50Mb 25.55Mb 25.60Mb 25.65Mb Reverse strand 227.56 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding Ensembl protein coding merged Ensembl/Havana Non-Protein Coding processed transcript RNA gene Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000162645 207.52 kb Forward strand Zmiz1-208 >protein coding ENSMUSP00000124... MobiDB lite Low complexity (Seg) Pfam Zmiz1, N-terminal tetratricopeptide repeat domain Zinc finger, MIZ-type PROSITE profiles Zinc finger, MIZ-type PANTHER PTHR10782:SF7 PTHR10782 Gene3D Zinc finger, RING/FYVE/PHD-type CDD cd16791 All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend frameshift variant splice region variant synonymous variant Scale bar 0 100 200 300 400 500 600 700 800 900 1072 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Load more

Recommended publications
  • Genome-Wide Analysis of Androgen Receptor Binding and Gene Regulation in Two CWR22-Derived Prostate Cancer Cell Lines
    Endocrine-Related Cancer (2010) 17 857–873 Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines Honglin Chen1, Stephen J Libertini1,4, Michael George1, Satya Dandekar1, Clifford G Tepper 2, Bushra Al-Bataina1, Hsing-Jien Kung2,3, Paramita M Ghosh2,3 and Maria Mudryj1,4 1Department of Medical Microbiology and Immunology, University of California Davis, 3147 Tupper Hall, Davis, California 95616, USA 2Division of Basic Sciences, Department of Biochemistry and Molecular Medicine, Cancer Center and 3Department of Urology, University of California Davis, Sacramento, California 95817, USA 4Veterans Affairs Northern California Health Care System, Mather, California 95655, USA (Correspondence should be addressed to M Mudryj at Department of Medical Microbiology and Immunology, University of California, Davis; Email: [email protected]) Abstract Prostate carcinoma (CaP) is a heterogeneous multifocal disease where gene expression and regulation are altered not only with disease progression but also between metastatic lesions. The androgen receptor (AR) regulates the growth of metastatic CaPs; however, sensitivity to androgen ablation is short lived, yielding to emergence of castrate-resistant CaP (CRCaP). CRCaP prostate cancers continue to express the AR, a pivotal prostate regulator, but it is not known whether the AR targets similar or different genes in different castrate-resistant cells. In this study, we investigated AR binding and AR-dependent transcription in two related castrate-resistant cell lines derived from androgen-dependent CWR22-relapsed tumors: CWR22Rv1 (Rv1) and CWR-R1 (R1). Expression microarray analysis revealed that R1 and Rv1 cells had significantly different gene expression profiles individually and in response to androgen.
    [Show full text]
  • Zmiz1a Zebrafish Mutants Have Defective Erythropoiesis, Altered Expression Of
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.14.444216; this version posted May 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. zmiz1a zebrafish mutants have defective erythropoiesis, altered expression of autophagy genes, and a deficient response to vitamin D Francisco Castillo-Castellanos1, Laura Ramírez1, and Hilda Lomelí1* 1Departamento de Genética del Desarrollo y Fisiología Molecular. Instituto de Biotecnología, Universidad Nacional Autónoma de México, *Corresponding author [email protected] Key words: erythropoiesis, zebrafish, autophagy, vitamin D response, ZMIZ1 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.14.444216; this version posted May 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT ZMIZ1 is a transcriptional coactivator that is related to members of the protein inhibitor of activated STAT (PIAS) family. ZMIZ1 regulates the activity of various transcription factors including the androgen receptor, p53, and Smad3. ZMIZ1 also interacts with Notch1 and selectively regulates Notch1 target genes relevant for T cell development and leukemogenesis in mammals. Human ZMIZ1 is additionally characterized as a latitude- dependent autoimmune disease (LDAD) risk gene, as it is responsive to vitamin D and has been associated with at least eleven blood cell traits. To address the function of ZMIZ1 in fish, we introduced CRISPR/Cas9 mutations in the zmiz1a gene in zebrafish. We observed that inactivation of zmiz1a in developing zebrafish larvae results in lethality at 15 dpf and delayed erythroid maturation.
    [Show full text]
  • Upregulation of 15 Antisense Long Non-Coding Rnas in Osteosarcoma
    G C A T T A C G G C A T genes Article Upregulation of 15 Antisense Long Non-Coding RNAs in Osteosarcoma Emel Rothzerg 1,2 , Xuan Dung Ho 3 , Jiake Xu 1 , David Wood 1, Aare Märtson 4 and Sulev Kõks 2,5,* 1 School of Biomedical Sciences, The University of Western Australia, Perth, WA 6009, Australia; [email protected] (E.R.); [email protected] (J.X.); [email protected] (D.W.) 2 Perron Institute for Neurological and Translational Science, QEII Medical Centre, Nedlands, WA 6009, Australia 3 Department of Oncology, College of Medicine and Pharmacy, Hue University, Hue 53000, Vietnam; [email protected] 4 Department of Traumatology and Orthopaedics, University of Tartu, Tartu University Hospital, 50411 Tartu, Estonia; [email protected] 5 Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, WA 6150, Australia * Correspondence: [email protected]; Tel.: +61-(0)-8-6457-0313 Abstract: The human genome encodes thousands of natural antisense long noncoding RNAs (lncR- NAs); they play the essential role in regulation of gene expression at multiple levels, including replication, transcription and translation. Dysregulation of antisense lncRNAs plays indispensable roles in numerous biological progress, such as tumour progression, metastasis and resistance to therapeutic agents. To date, there have been several studies analysing antisense lncRNAs expression profiles in cancer, but not enough to highlight the complexity of the disease. In this study, we investi- gated the expression patterns of antisense lncRNAs from osteosarcoma and healthy bone samples (24 tumour-16 bone samples) using RNA sequencing.
    [Show full text]
  • Colorectal Cancer Risk Genes Are Functionally Enriched in Regulatory
    www.nature.com/scientificreports OPEN Colorectal cancer risk genes are functionally enriched in regulatory pathways Received: 07 January 2016 Xi Lu1,*, Mingming Cao2,*, Su Han3, Youlin Yang1 & Jin Zhou4 Accepted: 12 April 2016 Colorectal cancer (CRC) is a common complex disease caused by the combination of genetic variants Published: 05 May 2016 and environmental factors. Genome-wide association studies (GWAS) have been performed and reported some novel CRC susceptibility variants. However, the potential genetic mechanisms for newly identified CRC susceptibility variants are still unclear. Here, we selected 85 CRC susceptibility variants with suggestive association P < 1.00E-05 from the National Human Genome Research Institute GWAS catalog. To investigate the underlying genetic pathways where these newly identified CRC susceptibility genes are significantly enriched, we conducted a functional annotation. Using two kinds of SNP to gene mapping methods including the nearest upstream and downstream gene method and the ProxyGeneLD, we got 128 unique CRC susceptibility genes. We then conducted a pathway analysis in GO database using the corresponding 128 genes. We identified 44 GO categories, 17 of which are regulatory pathways. We believe that our results may provide further insight into the underlying genetic mechanisms for these newly identified CRC susceptibility variants. Colorectal cancer (CRC) is the third most common form of cancer and the second leading cause of cancer-related death in the western world and1,2. CRC is a leading cause of cancer-related deaths in the United States, and its lifetime risk in the United States is about 7%1,3. CRC is a common complex disease caused by the combination of genetic variants and environmental factors1.
    [Show full text]
  • ZMIZ1 Preferably Enhances the Transcriptional Activity of Androgen Receptor with Short Polyglutamine Tract
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central ZMIZ1 Preferably Enhances the Transcriptional Activity of Androgen Receptor with Short Polyglutamine Tract Xiaomeng Li1,2,3*, Chunfang Zhu1,2, William H. Tu1, Nanyang Yang3, Hui Qin3, Zijie Sun1,2* 1 Department of Urology, Stanford University School of Medicine, Stanford, California, United States of America, 2 Department of Genetics, Stanford University School of Medicine, Stanford, California, United States of America, 3 The Key Laboratory of Molecular Epigenetics of MOE, Institute of Genetics and Cytology, Northeast Normal University, Changchun, The People’s Republic of China Abstract The androgen receptor (AR) is a ligand-induced transcription factor and contains the polyglutamine (polyQ) tracts within its N-terminal transactivation domain. The length of polyQ tracts has been suggested to alter AR transcriptional activity in prostate cancer along with other endocrine and neurologic disorders. Here, we assessed the role of ZMIZ1, an AR co- activator, in regulating the activity of the AR with different lengths of polyQ tracts as ARQ9, ARQ24, and ARQ35 in prostate cancer cells. ZMIZ1, but not ZMIZ2 or ARA70, preferably augments ARQ9 induced androgen-dependent transcription on three different androgen-inducible promoter/reporter vectors. A strong protein-protein interaction between ZMIZ1 and ARQ9 proteins was shown by immunoprecipitation assays. In the presence of ZMIZ1, the N and C-terminal interaction of the ARQ9 was more pronounced than ARQ24 and ARQ35. Both Brg1 and BAF57, the components of SWI/SNF complexes, were shown to be involved in the enhancement of ZMIZ1 on AR activity.
    [Show full text]
  • Combinatorial Targeting of the Androgen Receptor for Prostate
    Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy A thesis submitted to the University of Adelaide in the fulfilment of the requirements for the degree of Doctor of Philosophy By Sarah Louise Carter B.BiomolChem.(Hons) Dame Roma Mitchell Cancer Research Laboratories School of Medicine The University of Adelaide and The Hanson Institute March 2015 Contents Chapter 1: General Introduction ........................................................................................1 1.1 Background ..................................................................................................................2 1.2 Androgens and the Prostate ..........................................................................................3 1.3 Androgen Signalling through the Androgen Receptor .................................................4 1.3.1 The androgen receptor (AR) ..................................................................................4 1.3.2 Androgen signalling in the prostate .......................................................................6 1.4 Current Treatment Strategies for Prostate Cancer ........................................................8 1.4.1 Diagnosis ...............................................................................................................8 1.4.2 Localised disease .................................................................................................10 1.4.3 Relapse and metastatic disease ............................................................................13
    [Show full text]
  • NIH Public Access Author Manuscript Nat Genet
    NIH Public Access Author Manuscript Nat Genet. Author manuscript; available in PMC 2014 December 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nat Genet. 2014 June ; 46(6): 533–542. doi:10.1038/ng.2985. Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk Ben Zhang1, Wei-Hua Jia2, Koichi Matsuda3, Sun-Seog Kweon4,5, Keitaro Matsuo6, Yong- Bing Xiang7, Aesun Shin8,9, Sun Ha Jee10, Dong-Hyun Kim11, Qiuyin Cai1, Jirong Long1, Jiajun Shi1, Wanqing Wen1, Gong Yang1, Yanfeng Zhang1, Chun Li12, Bingshan Li13, Yan Guo14, Zefang Ren15, Bu-Tian Ji16, Zhi-Zhong Pan2, Atsushi Takahashi17, Min-Ho Shin4, Fumihiko Matsuda18, Yu-Tang Gao7, Jae Hwan Oh19, Soriul Kim10, Yoon-Ok Ahn9, Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)20, Andrew T Chan21,22, Jenny Chang-Claude23, Martha L. Slattery24, Colorectal Transdisciplinary (CORECT) Study20, Stephen B. Gruber25, Fredrick R. Schumacher25, Stephanie L. Stenzel25, Colon Cancer Family Registry (CCFR)20, Graham Casey25, Hyeong-Rok Kim26, Jin-Young Jeong11, Ji Won Park19,27, Hong-Lan Li7, Satoyo Hosono6, Sang-Hee Cho28, Michiaki Kubo17, Xiao-Ou Shu1, Yi-Xin Zeng2, and Wei Zheng1 1Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee, the United States 2State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, China 3Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo 108-8639, Japan 4Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, South Korea Corresponding author contact information: Wei Zheng, M.D., Ph.D., Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, 2525 West End Avenue, 8th Floor, Nashville, TN 37203-1738, Phone: (615) 936-0682; Fax: (615) 936-8241, [email protected].
    [Show full text]
  • Characterising Mechanisms of Aberrant Mutant Androgen Receptor Signalling in Advanced Prostate Cancer
    Characterising mechanisms of aberrant mutant androgen receptor signalling in advanced prostate cancer Wenrui Guo 120444241 Supervisors: Dr. Luke Gaughan Prof. Craig Robson Surgical Oncology Research Group Northern Institute for Cancer Research, Newcastle. September 2018 1 Abstract Prostate cancer (PC) is the most commonly diagnosed disease in the UK which causes approximately 10,000 deaths annually. Although an initially effective response to androgen deprivation therapy (ADT) occurs in most patients, the tumour normally recurs in a more aggressive form of the disease termed castrate resistant PC (CRPC) and is largely untreatable at this stage. In many cases, disease is driven by inappropriate androgen receptor (AR) signalling. It is therefore vital to have better understanding of mechanisms that re-activate AR and promote ADT resistance in the clinic and hence better treatments for advanced tumour. Activation of AR by testosterone is crucial for prostate growth and transformation. Anti- androgens, the second most common PC therapy after surgery, antagonise ligand binding to the receptor and hence deactivate AR signalling. In 2012, enzalutamide, a more potent agents in terms of availability to block AR was approved by the FDA and ENA as a second-generation anti- androgen for clinical usage. Although it demonstrated several advantages over its pervious counterpart bicalutamide, response rates of just 50% in CRPC patients and subsequent resistance observed in responders has limited its effectiveness. Critically, several lines of evidence from pre- clinical models and patient samples indicate that one particular resistant mechanism is the emergence of AR mutant(s), in part, driven by a specific AR mutation F876L that enables the compound to act as an agonist.
    [Show full text]
  • ZMIZ1 Preferably Enhances the Transcriptional Activity of Androgen Receptor with Short Polyglutamine Tract
    ZMIZ1 Preferably Enhances the Transcriptional Activity of Androgen Receptor with Short Polyglutamine Tract Xiaomeng Li1,2,3*, Chunfang Zhu1,2, William H. Tu1, Nanyang Yang3, Hui Qin3, Zijie Sun1,2* 1 Department of Urology, Stanford University School of Medicine, Stanford, California, United States of America, 2 Department of Genetics, Stanford University School of Medicine, Stanford, California, United States of America, 3 The Key Laboratory of Molecular Epigenetics of MOE, Institute of Genetics and Cytology, Northeast Normal University, Changchun, The People’s Republic of China Abstract The androgen receptor (AR) is a ligand-induced transcription factor and contains the polyglutamine (polyQ) tracts within its N-terminal transactivation domain. The length of polyQ tracts has been suggested to alter AR transcriptional activity in prostate cancer along with other endocrine and neurologic disorders. Here, we assessed the role of ZMIZ1, an AR co- activator, in regulating the activity of the AR with different lengths of polyQ tracts as ARQ9, ARQ24, and ARQ35 in prostate cancer cells. ZMIZ1, but not ZMIZ2 or ARA70, preferably augments ARQ9 induced androgen-dependent transcription on three different androgen-inducible promoter/reporter vectors. A strong protein-protein interaction between ZMIZ1 and ARQ9 proteins was shown by immunoprecipitation assays. In the presence of ZMIZ1, the N and C-terminal interaction of the ARQ9 was more pronounced than ARQ24 and ARQ35. Both Brg1 and BAF57, the components of SWI/SNF complexes, were shown to be involved in the enhancement of ZMIZ1 on AR activity. Using the chromatin immunoprecipitation assays (ChIP), we further demonstrated a strong recruitment of ZMIZ1 by ARQ9 on the promoter of the prostate specific antigen (PSA) gene.
    [Show full text]
  • A Network Inference Approach to Understanding Musculoskeletal
    A NETWORK INFERENCE APPROACH TO UNDERSTANDING MUSCULOSKELETAL DISORDERS by NIL TURAN A thesis submitted to The University of Birmingham for the degree of Doctor of Philosophy College of Life and Environmental Sciences School of Biosciences The University of Birmingham June 2013 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. ABSTRACT Musculoskeletal disorders are among the most important health problem affecting the quality of life and contributing to a high burden on healthcare systems worldwide. Understanding the molecular mechanisms underlying these disorders is crucial for the development of efficient treatments. In this thesis, musculoskeletal disorders including muscle wasting, bone loss and cartilage deformation have been studied using systems biology approaches. Muscle wasting occurring as a systemic effect in COPD patients has been investigated with an integrative network inference approach. This work has lead to a model describing the relationship between muscle molecular and physiological response to training and systemic inflammatory mediators. This model has shown for the first time that oxygen dependent changes in the expression of epigenetic modifiers and not chronic inflammation may be causally linked to muscle dysfunction.
    [Show full text]
  • The Mouse Intron-Nested Gene, Israa, Is Expressed in the Lymphoid Organs and Involved in T-Cell Activation and Signaling T
    Molecular Immunology 111 (2019) 209–219 Contents lists available at ScienceDirect Molecular Immunology journal homepage: www.elsevier.com/locate/molimm The mouse intron-nested gene, Israa, is expressed in the lymphoid organs and involved in T-cell activation and signaling T Noureddine Ben Khalafa, Wedad Al-Mashoora, Azhar Saeedb, Dalal Al-Mehataba, Safa Tahac, ⁎ Moiz Bakhietc, M. Dahmani Fathallaha, a Department of Life Sciences, Health Biotechnology Program, College of Graduates Studies, Arabian Gulf University, Manama, Bahrain b University of Michigan Medical School, MI, USA c Department of Molecular Medicine, Princess Al-Jawhara Center for Genetics and Inherited Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Bahrain ARTICLE INFO ABSTRACT Keywords: We have previously reported Israa, immune-system-released activating agent, as a novel gene nested in intron 8 of T-cell activation the mouse Zmiz1 gene. We have also shown that Israa encodes for a novel FYN-binding protein and might be Nested gene involved in the regulation of T-cell activation. In this report, we demonstrate that Israa gene product regulates Gene expression the expression of a pool of genes involved in T-cell activation and signaling. Real time PCR and GFP knock-in Elf1 expression analysis showed that Israa is transcribed and expressed in the spleen mainly by CD3+CD8+ cells as Fyn well as in the thymus by CD3+ (DP and DN), CD4+SP and CD8+SP cells at different developmental stages. We Yeast two-hybrid also showed that Israa is downregulated in T-cells following activation of T-cell receptor. Using yeast two-hybrid analysis, we identified ELF1, a transcription factor involved in T-cell regulation, as an ISRAA-binding partner.
    [Show full text]
  • Downloaded from the TCGA Portal Maintained by GDC
    www.nature.com/scientificreports OPEN Identifcation of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive Received: 13 November 2018 Accepted: 29 May 2019 and Hormone-resistant Prostate Published: xx xx xxxx Cancer Cells Maryam Ghashghaei1,2, Tamim M. Niazi1,3, Adriana Aguilar-Mahecha4, Kathleen Oros Klein1, Celia M. T. Greenwood 5,6,7,8, Mark Basik4,9 & Thierry M. Muanza1,2,3 Prostate cancer (PCa) is the most common cancer amongst men. A novel androgen receptor (AR) antagonist, enzalutamide (ENZA) has recently been demonstrated to enhance the efect of radiation (XRT) by impairing the DNA damage repair process. This study aimed to identify a radiosensitive gene signature induced by ENZA in the PCa cells and to elucidate the biological pathways which infuence this radiosensitivity. We treated LNCaP (AR-positive, hormone-sensitive PCa cells) and C4-2 (AR-positive, hormone-resistant PCa cells) cells with ENZA alone and in combination with androgen deprivation therapy (ADT) and XRT. Using one-way ANOVA on the gene expression profling, we observed signifcantly diferentially expressed (DE) genes in infammation-and metabolism-related genes in hormone-sensitive and hormone-resistant PCa cell lines respectively. Survival analysis in both the TCGA PRAD and GSE25136 datasets suggested an association between the expression of these genes and time to recurrence. These results indicated that ENZA alone or in combination with ADT enhanced the efect of XRT through immune and infammation-related pathways in LNCaP cells and metabolic-related pathways in C4-2 cells. Kaplan–Meier analysis and Cox proportional hazard models showed that low expression of all the candidate genes except for PTPRN2 were associated with tumor progression and recurrence in a PCa cohort.
    [Show full text]